IRB #

STUDY00016576

Title

A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to compare the safety and effects of atezolizumab (the study drug) with a placebo on people and their risk of RCC.

Medical Condition(s)

Renal Cell Carcinoma

Eligibility Criteria

RCC with a recent nephrectomy or metastasectomy. Further tests, procedures, and a review of your medical history will be done to confirm eligibility.

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Treatment will last for up to 1 year. Continued follow up will last for as long as your cancer has not returned.

Minors Included

No

Contact

Knight Clinical Trials
503-494-2751
trials@ohsu.edu

Sponsor

F. Hoffmann-La Roche Ltd

Recruitment End

12/07/2018

Compensation Provided

No


Go Back